A B S T R A C T The platelet
INTRODUCTION
Hemorrhage and thrombosis frequently complicate the clinical course of patients with the myeloproliferative diseases, polycythemia vera, myelofibrosis, and essential thrombocythemia. Quantitative as well as qualitative abnormalities of platelets may contribute to this disordered balance ofhemostasis. Thrombocytosis is present in the majority of patients with polycythemia vera (1) , in one-third of patients with myelofibrosis (2) , and is the major hematologic problem in patients with essential thrombocythemia. Although the high platelet count predisposes to thrombosis or hemorrhage, these events may occur in the setting of a normal platelet count (3) . Qualitative abnormalities which are common in myeloproliferative platelets include abnormal platelet morphology (4, 5) and an absent aggregation response to epinephrine (6) . Recently, decreased numbers ofa-adrenergic receptors were described in platelets of two patients with essential thrombocythemia (7) . Altered platelet metabolism of the prostaglandin precursor arachidonic acid has been reported in myeloproliferative platelets. The recent demonstration of a selective lipoxygenase deficiency in myeloproliferative platelets suggests that there may be a reciprocal increase in the cyclooxygenase pathway with subsequent increased aggregability of the myeloproliferative platelets (8) . Prostaglandin D,, a product of the cyclooxygenase pathway, inhibits platelet aggregation. Resistance to prostaglandin D2 and loss of prostaglandin D2 receptors on myeloproliferative platelets may also contribute to a thrombotic state (9, 10) .
Circulating immune complexes have been reported in the plasma of patients with myelofibrosis (11) . Immune complexes may interfere with platelet func-tion through interaction with a platelet Fe receptor (12, 13) . We have previously reported on the interaction of a fluorescein isothiocyanate (FITC)1-conjugated immune complex, keyhole limpet hemocyanin (KLH)-anti-KLH, with human platelets (14) . The majority of normal platelets bear a surface Fc receptor for this immune complex. In the present study, we describe an FITC-conjugated immune complex, ovalbumin-anti-ovalbumin, which reacts with only a small percentage of normal platelets. We have used this specific immune complex, as well as heat-aggregated human immunoglobulin (Ig)G, as a probe to study the differences between the Fc receptor of myeloproliferative platelets and of normal platelets. METHODS Preparation of platelets. Platelet-rich plasma (PRP), washed platelets, and fixed washed platelets were prepared from whole blood as previously described (14) . Platelet counts were performed visuially uinder phase-contrast microscopy and electronically using the model ZBI Coulter counter (Coulter Electronics, Inc., Hialeah, Fla.) according to the methods outlined by Gottfried et al. (15) . Platelet sizing was carried out in PRP from blood drawn into ACD. A size distribution analyzer was used (Coulter model P64), coupled with the model ZBI Coulter Counter fitted with a 70-,um aperture tube. The equipment was calibrated using 2.02 ,um3 latex particles (Coulter Electronics). The median Coulter volumes were calculated according to the method of von Behrens (16) .
Preparation of immune complexes and aggregated human IgG. The preparation of the FITC-conjugated KLH-rabbit anti-KLH complex has been previously described (14) . Rabbit antiserum to ovalbumin was prepared by immunization of rabbits with chicken egg albumin (Sigma Chemical Co., St. Louis, Mo.). The IgG was isolated by column chromatography ofthe antiserum on DEAE-cellulose (DE-52, Whatman Chemicals, Div. W. & R. Balston, Maidstone, Kent, England). The ovalbumin and the anti-ovalbumin IgG were conjugated to FITC at final ratios of FITC to protein of 0.5 (ovalbumin) and 1.1 (anti-ovalbumin) xg/ml.
Human IgG was prepared from pooled normal serum as previously described and heat aggregated by incubation at 63°C for 10 min just before use (14) .
Conjugation of protein A to IgG. To block the Fc region of IgG, the rabbit and the human IgG preparations were conjugated to protein A (Pharmacia Fine Chemicals, Piscataway, N. J.) by the method described by Rabellino et al. (17) .
Fluorescence assay for platelet Fc receptors. Platelets were incubated with immune complexes, washed, and examined by phase and fluorescence microscopy as previously described (14) . FITC-ovalbumin (30 ,ug/ml) and FITCanti-ovalbumin (3.5 mg/ml) were used. This ratio of antigen to antibody is in the range of antibody excess as determined by the method of Winchester et al. (18) , and gave maximal discrete platelet staining with minimal platelet clumping. To test the effect of thromiibini on the expression of the platelet Fc receptor, platelets were washed as described above, except that 4 mM EDTA was added to the buffer. 5 x 108 platelets were incubated with thrombin 0.25 U/ml at 37°C for 5 min. The platelets were then washed twice witlh bllifer containinig 1 mM p-tosyl-L-arginine methyl ester, and the platelet Fe receptor assay was performed.
Preincubation of platelets with von Willebrand factor and ristocetin was performed as previously described (14) .
Serotonin release by aggregated IgG, immune complexes, or thrombin. PRP was prepared as described above, centrifuged once at 600 g, and resuspended to a platelet couint of 4 x 108/ml. 1.5 ,ul [2'-_4C]5-hydroxytryptamine creatinine sulfate (50 ,uCi/mmol sp act, Amershanm Corp., Arlington Heights, Ill.) was added per milliliter suspended platelets, and after incubation in a circulating water bath at 37°C for 15 min, samples were taken to assess the uptake of serotonin. The platelets were then washed two times and resuspended at 15 x 108/ml for the experiments using immune complex, 6.5 x 108/ml for the experiments using aggregated IgG, and 5 x 108/ml for the thrombin experiments. 1 ,uM imipramine was added to prevent re-uptake of released serotonin. 200 Al samples of washed platelets were distributed to 1.5-ml conical capped polypropylene tubes for the experiments using immune complexes or thrombin, and 100-,lI portions were used for the experiments using aggregated IgG. For the experiments using immune complexes as the stimulus to platelet serotonin release, 25 Al of anti-ovalbumin (0.35 mg/ml) and 25 Al of serial dilutions of ovalbumin (100 ,ug/ml, final concentration of undiluted ovalbumin) were added. Antibody and antigen were also tested alone. For the experiments using human IgG, 100 pLI of serial dilutions of aggregated or unaggregated IgG (6.85 mg/ml, final concentration of undiluted IgG) was added. After incubation in a circulating water bath at 37°C for 30 min, the tubes were immersed in an ice bath and centrifuged at 8,000 g for 30 s; 100-,ul samples of each supernate were placed in scintillation vials containing 2.7 ml of Biofluor (New England Nuclear, Boston, Mass.). The radioactive samples were counted in a Searle Mark III liquid scintillation counter (Searle Diagnostics, Inc., Des Plaines, Ill.). To measure serotonin release by thrombin, 25-,ul samples of purified human thrombin (a gift from Dr. J. Fenton, Albany, N. Y.) in serial dilutions were added to the platelet suspensions. The final concentration of thrombin in the original dilution was 9.5 U/ml. The incubation procedure was performed according to the method of Weksler et al. (19) . In some experiments, the lactic dehydrogenase (LDH) activity was measured in the supernate of the experimental samples and compared to the LDH activity in the supernate of the control samples (20) .
Normal and patient donors. The characteristics of the normal and patient donors are outlined in Table I . The age, hematocrit, platelet count, and platelet size are noted. The normal donors were taking no medication and the absence of recent aspirin ingestion was confirmed by testing platelet aggregation in response to arachidonic acid (19) . The fluorescence assay for the platelet Fc receptor was also performed on three of the normal donors before and 12 h after the ingestion of 650 mg aspirin. Aggregation response to Carcinoma or lymphoma, 5; immune thrombocytopenia purpura in remission, 2; acute myelogenous leukemia, 1; femoral fracture, 1; megaloblastic anemia, 1; cerebrovascular accident, 1. 20 ,l. epinephrine HC1 (1: 1,000, Parke-Davis, Detroit, Mich.) added to 0.45 ml of PRP was tested in 16 patients with the myeloproliferative syndrome. There was no response to epinephrine in nine patients.
The patients with myeloproliferative syndrome were in all stages of the disease, including newly diagnosed, controlled on medication, and terminal phases. They were receiving various non-aspirin-containing medications; eight of the patients were taking no medication. Three patients had undergone splenectomy. The assays requiring platelet serotonin release were only performed on patients whose platelet counts were >200 x 103/ul.
RESULTS

Platelet Fc receptor staining
Normal donors. The platelets of 11 normal donors were reacted with the FITC-conjugated immune complex ovalbumin-anti-ovalbumin; one donor was studied on eight separate occasions. The mean number of platelets stained was 3.2+1.1%; no more than 5% platelets were stained in any normal donor preparation (Fig. 1) . Aspirin ingestion had no effect on the staining pattern.
Individual platelets stained in a focal or spotty pattern, there was no diffuse staining (Fig. 2a,b) . Rarely, a crescent pattern of staining was seen (Fig.  2c,d ). The fluorescent staining was not limited to large or small platelets, and it was impossible to predict by phase microscopy which platelets would or would not stain (Fig. 2e,f Myeloproliferative syndrome. Platelets from patients with myeloproliferative disorders were strikingly different from normal platelets (Fig. 3) . 76.4+16% of the myeloproliferative platelets stained with the immune complex, ovalbumin-anti-ovalbumin (Fig. 1) . 18 (Fig. 1) . One patient had 1.5% staining; the patient with the highest percentage of stained platelets (30%) was in the blast phase of the disease.
Reactive thrombocytosis. Nine patients with reactive thrombocytosis were studied (Fig. 1) (Fig. 4) . Mean serotonin release >25% was found in the range of 55 to 3,500 ,ug aggregated IgG/ml. Platelet serotonin release in response to aggregated IgG in the five myeloproliferative patients with normal serotonin uptake was found to be markedly increased compared with the normal patients (Fig. 4) . Peak serotonin release (78.8±9.5%) by aggregated IgG occurred at 438 ,ug aggregated IgG/ml. Mean serotonin release > 25% began at 3.5 ,ug/ml, release >70% began at 57 ,ug/ml and both continued to the highest concentration, 7,300 ,g/ml. This pattern was similar in all five patients. There was no relationship to hematocrit (range 26-55%), platelet count (range 155-1,800 x 103/,ul), or platelet size (6.06-11.02 ,um3). There was no serotonin release >5% from normal or myeloproliferative platelets by any concentration of unaggregated IgG or by aggregated IgG conjugated to protein A. There was Serotonin release from platelets by the immune complex ovalbumin-anti-ovalbumin was studied in three normal donors and three patients with myeloproliferative diseases (two polycythemia vera; one myelofibrosis) (Fig. 5) . In both the normal and patient donors, maximum serotonin release occurred in the range of antibody excess. This correlates with the optimal range for staining of washed platelets with the FITC-conjugated immune complex. Myeloproliferative platelets released >60% serotonin in response to immune complexes of all antigen-antibody ratios. The maximum serotonin release was 92%. In contrast, normal platelets released a maximum of 39% serotonin, and >30% serotonin only over a small range of antigen concentration (6-15 ,ug/ml). Neither normal nor myeloproliferative platelets released serotonin in response to antigen or antibody alone, and there was no LDH release after incubation of the platelets with the immune complexes.
The platelets of five patients with myeloproliferative disease and five normal donors were tested for serotonin release in response to serial dilutions of thrombin. There was no increased release of serotonin by the myeloproliferative platelets compared with normal (Fig. 6 ).
DISCUS SION
This study demonstrates the increased expression of a platelet Fc receptor in myeloproliferative platelets. The interaction between the immune complex and the platelets is dependent on an intact antibody Fc region and is blocked by heat-aggregated IgG. We have previously described the interaction of a (12, 13, 23) . This reaction is dependent on the Fc region of IgG and is mediated by a platelet Fc receptor. In the present study, the release of ["4C]serotonin by the immune complex ovalbumin-anti-ovalbumin and by aggregated IgG was exaggerated in myeloproliferative platelets and was not found if thrombin was used as a stimulus to serotonin release. These results suggest that the increased expression of surface Fc receptors in the myeloproliferative platelets leads to increased reactivity to immune complexes as evidenced by the increased serotonin release.
The increased expression of Fc receptors in myeloproliferative platelets may arise at the stem cell or megakaryocyte level or may occur after the platelets have been released into the circulation. Glucose 6-phosphate dehydrogenase isoenzyme analysis of circulating platelets, neutrophils, and erythrocytes in the myeloproliferative diseases points to a common neoplastic stem cell origin for these three cell types (24, 25) . Recently, Gilbert et al. (26) described an increase in IgG receptor-bearing neutrophils in patients with agnogenic myeloid metaplasia and polycythemia vera. As in the present study, patients with chronic myelogenous leukemia did not share this increased expression of an Fc receptor. Thus, the finding of increased Fc receptor-bearing neutrophils and platelets raises the possibility that in some circumstances there may be a transmitted alteration in a stem cell precursor that allows this increased expression.
The increased platelet Fc receptor expression in the myeloproliferative disorders does not appear to reflect the expansion of one population of normal platelets, for example, young platelets. The platelets of patients with postsplenectomy thrombocytosis, who might be presumed to have a larger population of young, more active platelets, do not have increased Fc receptors (Fig. 1) . In addition, the platelets of two patients with immune thrombocytopenia in remission were studied and found to be normal. Fc receptor analysis of different sized platelets from normal donors did not localize the Fc receptor-positive platelets to one size population.2 It is interesting that certain patients with malignant disease demonstrated increased staining despite the absence of evidence of a myeloproliferative disease. This suggests that the increased expression of the platelet Fc receptor may not necessarily reflect a stem cell abnormality but rather an abnormality in the platelet environment.
The modulation of Fc receptor expression has been studied in experimental systems. For example, gluicocorticoids inhibit the expression of an Fc receptor on a human promyelocytic cell line (27) . In other myeloid leukemia lines, the Fc receptor can be induced by a macrophage and granulocyte-inducing protein. In turn, this regulatory protein can be induced by a surface-acting compound, lipid A (28). It is possible that similar humoral factors act to modulate platelet Fc receptor expression in the myeloproliferative disorders. Membrane receptors for peptide hormones may be regulated by the ambient concentration of the specific hormone (29) . Circulating immune complexes, which are present in some patients with myeloproliferative disease (11) , may elicit the expression of a specific population of platelet Fc receptors. It is of some interest that in preliminary studies, six of seven myeloproliferative patients reported in this study with >80% platelet staining by the immune complex ovalbumin-anti-ovalbumin also had elevated circulating immune complexes (30) . Further studies are underway to explore this relationship.
The role of the increased platelet Fc receptor expression in the pathogenesis of the hemorrhagic or thrombotic diathesis found in patients with the myeloproliferative syndromes remains to be determined. Our results show that the FITC-conjugated immune complexes used in these studies are not taken up by platelets when the incubation is performed in plasma. However, studies by Pfueller et al. (13) show that soluble radiolabeled IgG aggregates can bind to normal platelets in plasma, and it is possible that certain circulating immune complexes may also bind to platelets in plasma. Our studies further show that the avidity of immune complexes for platelets may depend on the nature of the antigen, the size of the complex, or on the exact ratio of antigen to antibody. In a clinical setting, it is possible that selected immune complexes bind to myeloproliferative platelets and compromise normal hemostatic functions.
